{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:28:38Z","timestamp":1781760518939,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-022-02369-5","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T16:02:23Z","timestamp":1658592143000},"page":"429-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study"],"prefix":"10.1007","volume":"315","author":[{"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailyn","family":"Valido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"issue":"4","key":"2369_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol 29(4):619\u2013644","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"2369_CR2","first-page":"17","volume":"11","author":"C Vinkel","year":"2018","unstructured":"Vinkel C, Thomsen SF (2018) Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol 11(10):17\u201323","journal-title":"J Clin Aesthet Dermatol"},{"issue":"20","key":"2369_CR3","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1001\/jama.2017.16691","volume":"318","author":"DML Saunte","year":"2017","unstructured":"Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318(20):2019\u20132032","journal-title":"JAMA"},{"issue":"6","key":"2369_CR4","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjd.19435","volume":"183","author":"JR Ingram","year":"2020","unstructured":"Ingram JR (2020) The epidemiology of hidradenitis suppurativa. Br J Dermatol 183(6):990\u2013998","journal-title":"Br J Dermatol"},{"key":"2369_CR5","unstructured":"Ballard K, Shuman VL (2021) Hidradenitis suppurativa. In: StatPearls. Treasure Island, FL."},{"issue":"1","key":"2369_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/jdv.16677","volume":"35","author":"TV Nguyen","year":"2021","unstructured":"Nguyen TV et al (2021) Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 35(1):50\u201361","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2369_CR7","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jaad.2020.04.009","volume":"83","author":"AB Lyons","year":"2020","unstructured":"Lyons AB et al (2020) Emerging medical treatments for hidradenitis suppurativa. J Am Acad Dermatol 83(2):554\u2013562","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2369_CR8","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","volume":"82","author":"RG Casseres","year":"2020","unstructured":"Casseres RG et al (2020) Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 82(6):1524\u20131526","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2369_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjd.17822","volume":"181","author":"L Prussick","year":"2019","unstructured":"Prussick L et al (2019) Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol 181(3):609\u2013611","journal-title":"Br J Dermatol"},{"issue":"6","key":"2369_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/14712598.2020.1732918","volume":"20","author":"M Rosales Santillan","year":"2020","unstructured":"Rosales Santillan M et al (2020) Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther 20(6):621\u2013633","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"2369_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422\u2013434","journal-title":"N Engl J Med"},{"issue":"1","key":"2369_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.det.2015.08.002","volume":"34","author":"IM Miller","year":"2016","unstructured":"Miller IM, McAndrew RJ, Hamzavi I (2016) Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin 34(1):7\u201316","journal-title":"Dermatol Clin"},{"issue":"1","key":"2369_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.det.2015.07.002","volume":"34","author":"JR Ingram","year":"2016","unstructured":"Ingram JR (2016) The genetics of hidradenitis suppurativa. Dermatol Clin 34(1):23\u201328","journal-title":"Dermatol Clin"},{"issue":"2","key":"2369_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bjd.18135","volume":"182","author":"E Keary","year":"2020","unstructured":"Keary E, Hevey D, Tobin AM (2020) A qualitative analysis of psychological distress in hidradenitis suppurativa. Br J Dermatol 182(2):342\u2013347","journal-title":"Br J Dermatol"},{"issue":"2","key":"2369_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jdv.12567","volume":"29","author":"E Shavit","year":"2015","unstructured":"Shavit E et al (2015) Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 29(2):371\u2013376","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2369_CR16","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijwd.2019.06.026","volume":"5","author":"A Cartron","year":"2019","unstructured":"Cartron A, Driscoll MS (2019) Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol 5(5):330\u2013334","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"2369_CR17","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/bjd.15998","volume":"178","author":"IM Miller","year":"2018","unstructured":"Miller IM et al (2018) Hidradenitis suppurativa is associated with myocardial infarction, but not stroke or peripheral arterial disease of the lower extremities. Br J Dermatol 178(3):790\u2013791","journal-title":"Br J Dermatol"},{"issue":"4","key":"2369_CR18","first-page":"204","volume":"149","author":"AD Cohen","year":"2010","unstructured":"Cohen AD et al (2010) The quality indigators program in Clalit Health Services: the first decade. Harefuah 149(4):204\u2013209","journal-title":"Harefuah"},{"issue":"5","key":"2369_CR19","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/bjd.14024","volume":"173","author":"T Tzellos","year":"2015","unstructured":"Tzellos T et al (2015) Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol 173(5):1142\u20131155","journal-title":"Br J Dermatol"},{"issue":"7","key":"2369_CR20","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/jdv.14076","volume":"31","author":"JC Pascual","year":"2017","unstructured":"Pascual JC et al (2017) Assessment of subclinical atherosclerosis in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 31(7):1229\u20131238","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2369_CR21","doi-asserted-by":"publisher","first-page":"2450401","DOI":"10.1155\/2017\/2450401","volume":"2017","author":"D Jimenez-Gallo","year":"2017","unstructured":"Jimenez-Gallo D et al (2017) The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm 2017:2450401","journal-title":"Mediators Inflamm"},{"issue":"2","key":"2369_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jaad.2018.02.040","volume":"79","author":"B Lockshin","year":"2018","unstructured":"Lockshin B, Balagula Y, Merola JF (2018) Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol 79(2):345\u2013352","journal-title":"J Am Acad Dermatol"},{"key":"2369_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.molimm.2019.01.008","volume":"107","author":"MD Mora-Ruiz","year":"2019","unstructured":"Mora-Ruiz MD et al (2019) Role of interleukin-17 in acute myocardial infarction. Mol Immunol 107:71\u201378","journal-title":"Mol Immunol"},{"key":"2369_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.molimm.2018.12.014","volume":"105","author":"L Zhang","year":"2019","unstructured":"Zhang L et al (2019) IL-17A contributes to myocardial ischemic injury by activating NLRP3 inflammasome in macrophages through AMPKalpha\/p38MAPK\/ERK1\/2 signal pathway in mice. Mol Immunol 105:240\u2013250","journal-title":"Mol Immunol"},{"issue":"1","key":"2369_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamadermatol.2019.3412","volume":"156","author":"S Reddy","year":"2020","unstructured":"Reddy S et al (2020) Incidence of myocardial infarction and cerebrovascular accident in patients with hidradenitis suppurativa. JAMA Dermatol 156(1):65\u201371","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2369_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","volume":"152","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Gislason GH, Hansen PR (2016) Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol 152(4):429\u2013434","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2369_CR27","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jaad.2019.06.016","volume":"81","author":"S Reddy","year":"2019","unstructured":"Reddy S, Strunk A, Garg A (2019) All-cause mortality among patients with hidradenitis suppurativa: a population-based cohort study in the United States. J Am Acad Dermatol 81(4):937\u2013942","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2369_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamadermatol.2017.5890","volume":"154","author":"S Hessam","year":"2018","unstructured":"Hessam S et al (2018) A novel severity assessment scoring system for hidradenitis suppurativa. JAMA Dermatol 154(3):330\u2013335","journal-title":"JAMA Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-022-02369-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T12:06:56Z","timestamp":1678968416000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-022-02369-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["2369"],"URL":"https:\/\/doi.org\/10.1007\/s00403-022-02369-5","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"3 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ADC served as an advisor, investigator, or speaker for Abbvie, BI, Dexcel Pharma, Janssen, Novartis, Perrigo, Pfizer, and Rafa. KK, KV, and JMC do not have conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}